These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 17228460)

  • 1. Vaccines. From Israel: a T-cell vaccine.
    TreatmentUpdate; 2005; 17(1):11-2. PubMed ID: 17228460
    [No Abstract]   [Full Text] [Related]  

  • 2. A therapeutic HIV-1 vaccine enhances anti-HIV-1 immune responses in patients under highly active antiretroviral therapy.
    Tung FY; Tung JK; Pallikkuth S; Pahwa S; Fischl MA
    Vaccine; 2016 Apr; 34(19):2225-32. PubMed ID: 27002500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candidate vaccines for immunotherapy in HIV.
    Gotch FM; Imami N; Hardy G
    HIV Med; 2001 Oct; 2(4):260-5. PubMed ID: 11737407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study.
    Harrer T; Plettenberg A; Arastéh K; Van Lunzen J; Fätkenheuer G; Jaeger H; Janssens M; Burny W; Collard A; Roman F; Loeliger A; Koutsoukos M; Bourguignon P; Lavreys L; Voss G
    Vaccine; 2014 May; 32(22):2657-65. PubMed ID: 24144472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine.
    Gahery H; Daniel N; Charmeteau B; Ourth L; Jackson A; Andrieu M; Choppin J; Salmon D; Pialoux G; Guillet JG
    AIDS Res Hum Retroviruses; 2006 Jul; 22(7):684-94. PubMed ID: 16831093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccines. From Brazil and France: a vaccine against HIV may lower viral load.
    TreatmentUpdate; 2005; 17(1):10-1. PubMed ID: 17228459
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatitis A vaccination and immunological parameters in HIV-infected patients.
    Kourkounti S; Papaizos V; Leuow K; Kordosis T; Antoniou C
    Viral Immunol; 2013 Oct; 26(5):357-63. PubMed ID: 24044625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cells versus HIV-1: fighting exhaustion as well as escape.
    Robinson HL
    Nat Immunol; 2003 Jan; 4(1):12-3. PubMed ID: 12496971
    [No Abstract]   [Full Text] [Related]  

  • 10. A look at HIV immune research. Interview by Alan Huff.
    Landay A
    Res Initiat Treat Action; 2000 Sep; 6(3):30-3. PubMed ID: 11708165
    [No Abstract]   [Full Text] [Related]  

  • 11. Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial.
    Gudmundsdotter L; Wahren B; Haller BK; Boberg A; Edbäck U; Bernasconi D; Buttò S; Gaines H; Imami N; Gotch F; Lori F; Lisziewicz J; Sandström E; Hejdeman B
    Vaccine; 2011 Jul; 29(33):5558-66. PubMed ID: 21300092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased soluble Fas in HIV-infected hemophilia patients with CD4+ and CD8+ cell count increases and viral load and immune complex decreases.
    Daniel V; Süsal C; Weimer R; Zimmermann R; Huth-Kühne A; Opelz G
    AIDS Res Hum Retroviruses; 2001 Mar; 17(4):329-35. PubMed ID: 11242519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of a year of highly active antiretroviral therapy on immune reconstruction and cytokines in HIV/AIDS patients.
    Yao Y; Luo Y; He Y; Zheng Y; Zhang Q; Zhou H; Zeng S; Chen Z; He B; He M
    AIDS Res Hum Retroviruses; 2013 Apr; 29(4):691-7. PubMed ID: 23151174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ T cell recovery beyond the first year of complete suppression of viral replication during highly active antiretroviral therapy is not influenced by CD8+ T cell activation.
    Benito JM; Lopez M; Lozano S; Ballesteros C; Capa L; Martinez P; Gonzalez-Lahoz J; Soriano V
    J Infect Dis; 2005 Dec; 192(12):2142-6. PubMed ID: 16288380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Keystone HIV pathogenesis and vaccine development report.
    Hardy G
    GMHC Treat Issues; 2004; 18(5-6):6-8. PubMed ID: 15359437
    [No Abstract]   [Full Text] [Related]  

  • 16. Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy.
    Torti C; Prosperi M; Motta D; Digiambenedetto S; Maggiolo F; Paraninfo G; Ripamonti D; Cologni G; Fabbiani M; Caputo SL; Sighinolfi L; Ladisa N; El-Hamad I; Quiros-Roldan E; Frank I
    Clin Microbiol Infect; 2012 May; 18(5):449-58. PubMed ID: 21919996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.
    Stone SF; Price P; French MA
    HIV Med; 2005 Jul; 6(4):278-83. PubMed ID: 16011533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Policy rebuttal. HIV vaccine trial justified.
    McNeil JG; Johnston MI; Birx DL; Tramont EC
    Science; 2004 Feb; 303(5660):961. PubMed ID: 14963313
    [No Abstract]   [Full Text] [Related]  

  • 19. Novel T-cell-based vaccines via arming polyclonal CD4
    Xu A; Freywald A; Xiang J
    Immunotherapy; 2016 Nov; 8(11):1265-1269. PubMed ID: 27993084
    [No Abstract]   [Full Text] [Related]  

  • 20. Apoptosis of HIV-specific CD8+ T cells: an HIV evasion strategy.
    Petrovas C; Mueller YM; Katsikis PD
    Cell Death Differ; 2005 Aug; 12 Suppl 1():859-70. PubMed ID: 15818412
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.